Exelixis
EXEL
#2109
Rank
A$11.30 B
Marketcap
$39.63
Share price
-1.53%
Change (1 day)
18.25%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of June 2024 : A$1.50 B

According to Exelixis's latest financial reports the company has A$1.50 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31A$1.46 B-24.02%
2022-12-31A$1.92 B-4.7%
2021-12-31A$2.01 B28.86%
2020-12-31A$1.56 B29.15%
2019-12-31A$1.21 B23.23%
2018-12-31A$0.98 B98.08%
2017-12-31A$0.49 B-14.71%
2016-12-31A$0.58 B153.93%
2015-12-31A$0.22 B30.34%
2014-12-31A$0.17 B-35.27%
2013-12-31A$0.27 B-31.5%
2012-12-31A$0.39 B109.46%
2011-12-31A$0.18 B17.92%
2010-12-31A$0.16 B-29.24%
2009-12-31A$0.22 B-40.23%
2008-12-31A$0.37 B22.26%
2007-12-31A$0.31 B36.95%
2006-12-31A$0.22 B11.71%
2005-12-31A$0.20 B1.3%
2004-12-31A$0.20 B-37.13%
2003-12-31A$0.31 B-19.05%
2002-12-31A$0.39 B-11.69%
2001-12-31A$0.44 B121.64%
2000-12-31A$0.20 B1817.12%
1999-12-31A$10.5 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
A$5.66 B 276.67%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$10.92 B 626.96%๐Ÿ‡ซ๐Ÿ‡ท France
A$17.02 B 1,033.13%๐Ÿ‡บ๐Ÿ‡ธ USA
A$9.97 B 563.97%๐Ÿ‡บ๐Ÿ‡ธ USA
A$13.95 B 828.24%๐Ÿ‡บ๐Ÿ‡ธ USA
A$38.20 B 2,442.42%๐Ÿ‡บ๐Ÿ‡ธ USA
A$10.65 B 608.68%๐Ÿ‡บ๐Ÿ‡ธ USA
A$42.53 M-97.17%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.11 B-92.28%๐Ÿ‡บ๐Ÿ‡ธ USA